Guidant to apply for new ICD (implantable cardioverter defibrillator) indication
This article was originally published in Clinica
Guidant plans to apply to the US FDA to expand the use of its implantable cardioverter defibrillators (ICDs) to include their use in patients at risk from sudden unexplained death syndrome (SUDS). The company's decision is based on results from the DEBUT (Defibrillator vs Beta-blockers for Unexplained Death in Thailand) study, which showed that ICDs were better than drugs in saving lives of people with SUDS who have no structural heart disease and a normal ejection fraction.
You may also be interested in...
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.
A medtech industry group is asking the Trump administration to clarify if small medical device companies that have equity investors qualify for small business loans and forgiveness under the coronavirus relief package.
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.